← Back to headlines
Grifols Reports Strong Biopharma Growth Driven by Key Products
Grifols, S.A. (GRFS) has reported robust growth in its biopharma sector, primarily attributed to the strong performance of its products Gamunex and Yimmugo.
2 Jun, 14:10 — 2 Jun, 14:10
Sources
Showing 1 of 1 sources
